Putnam Investments’s Tenaya Therapeutics TNYA Stock Holding History

Putnam Investments’s Portfolio TNYA Stock Details TNYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-58,821	Closed	-$150K	–	1224
2023 Q3	$150K	Buy	+58,821	New	+$246K	﹤0.01%	1133

Other funds holding TNYA

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments's TNYA Position: Q4 2023 in Review

Putnam Investments sold out of Tenaya Therapeutics (TNYA) in Q4 2023, closing a stake of 58,821 shares — an estimated $150K sold.

Putnam Investments first reported a position in TNYA in Q3 2023 and held it in 1 quarter. The position peaked at $150K in Q3 2023. 74 funds tracked by Wall St. Rank hold TNYA as of Q4 2023.

Putnam Investments reported no remaining Tenaya Therapeutics position as of Q4 2023 after selling out during the quarter.
Putnam Investments sold 58,821 Tenaya Therapeutics shares in Q4 2023, an estimated $150K.
Putnam Investments first reported a position in Tenaya Therapeutics in Q3 2023 and held it in 1 quarter.
Putnam Investments's Tenaya Therapeutics position peaked at $150K in Q3 2023.
74 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q4 2023.

Based on Putnam Investments's 13F filing for Q4 2023, filed 14 Feb 2024.